Mainz (DPA / LRS) – Mainz researchers will receive 13 million euros from the German Research Foundation for the discovery of the smallest active material in tumor therapy. The collaborative research center aims to be able to permanently eliminate minimal residual diseases, such as undiscovered, uncontrolled metastases, the University of Mainz announced on Friday. It is involved with other departments of Johannes Gutenberg University in the Collaborative Research Center and the Max Planck Institute for Polymer Research in Mainz.

University Medicine explained that the renewed funding underscores the importance of Mainz as a science space in the fields of biotechnology, immunology and polymer research.

The research has been funded for eight years; Renewed funding covers a period of four years. The pioneering work of Ugur Sahin and Özlem Türeci, founders of Biontech, suggests that these small carriers of nanoparticle size may have “excellent results” in clinical application and develop immunotherapeutics based on messenger ribonucleic acid . Both worked as scientists at Mainz University Medical Center for many years.

© DPA-InfoCom, DPA: 210528-99-778864 / 3